FDA imposes clinical hold on Regenxbio gene therapy trial due to safety concerns

The FDA has suspended a Regenxbio gene therapy trial following the emergence of new safety data. This marks a recurring regulatory intervention for the program, highlighting ongoing challenges in the clinical development of this specific therapeutic candidate.